Xigris (Drotrecogin alfa) is not an antibiotic but is approved for the specific indication of sepsis because of its anticoagulant properties.
Xigris (Drotrecogin alfa) is a drug approved by the Food and Drug Administration for the reduction of mortality in adult patients with severe sepsis who have a high risk of death. Xigris (Drotrecogin alfa) is placed under the class of serine proteases and it has anticoagulant, anti-thrombotic, anti-inflammatory, and profibrinolytic properties.
Xigris (drotrecogin alfa (activated)) is a recombinant form of human activated protein C. Drotrecogin alfa (activated) is a serine protease with the same amino acid sequence as human plasma-derived activated protein C.
Xigris (drotrecogin alfa) is indicated or used for the reduction of mortality in adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high risk of death.
